Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Liabilities and Shareholders Equity: 2016-2025

Historic Liabilities and Shareholders Equity for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to $506.9 million.

  • Rhythm Pharmaceuticals' Liabilities and Shareholders Equity rose 39.42% to $506.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 24.07%. This contributed to the annual value of $392.3 million for FY2024, which is 17.89% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $506.9 million for Q3 2025, which was up 35.99% from $372.7 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $506.9 million for Q3 2025, and its period low was $258.7 million during Q1 2024.
  • Its 3-year average for Liabilities and Shareholders Equity is $364.1 million, with a median of $363.6 million in 2024.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Liabilities and Shareholders Equity spiked by 65.13% in 2021, and later crashed by 32.54% in 2022.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Liabilities and Shareholders Equity stood at $329.5 million in 2021, then increased by 16.07% to $382.5 million in 2022, then decreased by 13.00% to $332.7 million in 2023, then increased by 17.89% to $392.3 million in 2024, then skyrocketed by 39.42% to $506.9 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $506.9 million for Q3 2025, versus $372.7 million for Q2 2025 and $386.7 million for Q1 2025.